Amgevita (adalimumab) Formulation | Amgen


Citrate-free formulations may be associated with reduced injection site pain when compared with citrate-containing formulations1–3

Reduced injection site pain may improve compliance to treatment.4
Injection site pain perception from bioequivalence clinical trials: Results of an exploratory analysis3,4*
CI = Confidence interval
*The study reports results of patient perception of injection site pain and injection site reactions from two bioequivalence trials with AMGEVITA® compared with citrate-containing adalimumab in rheumatoid arthritis and plaque psoriasis. In both trials, injection site pain was an exploratory objective. Subject perception of injection site pain assessed after injection on a 100 mm horizontal visual analogue scale, with the left-hand extreme described as ‘No pain at all’ and right-hand extreme as ‘A lot of pain’. Measurements taken within 5 minutes of injection in the safety analysis set.
The citrate-containing adalimumab formulation studied above is no longer available in the majority of European markets.
  1. AMGEVITA® (adalimumab) Summary of Product Characteristics. Available at: Last revised March 2020.
  2. Nash P, et al. Rheumatol Ther. 2016;3:257–70.
  3. Laursen T, et al. Basic Clin Pharmacol Toxicol. 2006;98:212–21.
  4. Krishnan E, et al. EULAR Amsterdam, Netherlands, 2018; PosterFRI0115.
  5. Krishnan E, et al. ECCO Vienna, Austria, 2018; Poster P497.

The information contained in this website is for European healthcare professionals only

I understand and confirm I am an EU healthcare professional
Read more >
I am not an EU healthcare professional
Read more >
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.